BUSINESS WIRE: European Data Suggest Switching Pat...

BUSINESS WIRE: European Data Suggest Switching Patients to IgPro20 May
Significantly Reduce

Drug Administration Volume



MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS
BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
------------------------------------------------------------------------



KING OF PRUSSIA, Pa. --(BUSINESS WIRE)--01.03.2010--

Data from a European multicenter (non-IND study) showing that patients with
PI who switched to IgPro20 from previously available SCIg formulations
achieved comparable IgG trough levels without dosage adjustment, resulting
in significantly less administration volume. The data were presented at the
American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in
New Orleans, US.

The data were based on a sub-analysis of a multicenter study of 51 patients
with PID switched from their previous treatment to an equivalent dose of
weekly subcutaneous infusions of IgPro20. Nineteen patients were switched
from other SCIg therapies, including 16% subcutaneous immunoglobulin
(n=13), as well as Subcuvia (n=4) and Gammanorm (n=2), two formulations not
approved in the US. The study took place over a 17-week period, with IgG
trough levels evaluated at baseline, and Weeks 4, 8, 12, 13, 14, 15, 16 and
17. Trough levels were compared with pre-study levels. No apparent
difference in trough levels between IgPro20 and previous 16 percent SCIg
were found.

“There are currently little data available on switching from one SCIg to
another,” said Dr. Stephen Jolles, Consultant Clinical Immunologist,
University Hospital of Wales, U.K. “Our study suggests that the majority of
patients can be switched to IgPro20 without dose adjustment, resulting in
significantly less administration volume, providing reassuring evidence for
physicians whose patients may require a change in treatment.”

Primary immunodeficiencies (PIs) are a group of nearly 100 types of
disorder that result from the defective development and maturation of the
immune system. The clinical hallmark of these disorders is increased
susceptibility to infection. Immunoglobulin replacement therapy is
indicated for patients who suffer from recurrent infections due to a lack
of protective antibodies. Repeated infections can lead to organ damage,
which over time can become life-threatening. In some severe cases of PI,
infections may result in a patient being hospitalized repeatedly. Some
infections, such as meningitis, can even result in death. Most types of PI
are inherited, but in some cases the cause is unknown.

No single treatment works for all types of PI. Infusions of replacement
antibodies (immunoglobulins) can help supplement the immune system to
prevent infection in the nearly three-quarters of people living with PI
whose disease is due to an antibody deficiency.

IgPro20 is currently being reviewed by the FDA for use as weekly
immunoglobulin replacement therapy in patients with PI. If approved, it
will represent a new treatment option for patients who want the freedom and
convenience of self-administering their replacement therapy.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry.
Committed to saving lives and improving the quality of life for people with
rare and serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide. CSL Behring therapies
are indicated for the treatment of coagulation disorders including
hemophilia and von Willebrand disease, primary immune deficiencies and
inherited respiratory disease. The company's products are also used in
cardiac surgery, organ transplantation, burn treatment and to prevent
hemolytic diseases in newborns. CSL Behring operates one of the world's
largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary
of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in
Melbourne, Australia. For more information, visit www.cslbehring.com.

[CT]

Kontakt: CSL Behring Sheila A. Burke, Director, Communications & Public
Relations Worldwide Commercial Operations Tel: 610-878-4209 Cell:
484-919-2618 Sheila.Burke@cslbehring.com or Weber Shandwick Emma
Spencer-Smith Tel: +44 207 067 0307 espencer-smith@webershandwick.com

Pressekontakt:
BUSINESS WIRE
A Berkshire Hathaway Company
Sandweg 94 F
D-60316 Frankfurt a. M.
t. +49 (0)69-91 50 66-0
f. +49 (0)69-91 50 66-50
e. germany@businesswire.com
w. www.businesswire.de oder www.businesswire.com



vwd Vereinigte Wirtschaftsdienste AG
Tilsiter Straße 1
60487 Frankfurt am Main
Telefon: +49 69 50701-0
Telefax: +49 69 50701-126
E-Mail: info@vwd.com
www.vwd.comPermalink: http://www.ddpdirect.de/business_wire_european_data_suggest_switching_patients_to_igpro20_may_significantly_reduce_55749.html (Dies ist eine über ddp direct verbreitete Pressemitteilung. Für denInhalt ist ausschließlich das herausgebende Unternehmen verantwortlich.) ddp direct - mehr Medien